Chikungunya Fever - Pipeline Review, H1 2018

SKU ID : GMD-GMDHC10347IDB 11429968

Publishing Date : 17-Apr-2018

No. of pages : 100

PRICE
2000
6000


  • Chikungunya Fever - Pipeline Review, H1 2018

    Summary

    Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Chikungunya Fever - Pipeline Review, H1 2018, provides an overview of the Chikungunya Fever (Infectious Disease) pipeline landscape.

    Chikungunya is a viral disease transmitted to humans by the bite of infected Aedes aegypti mosquitoes. Chikungunya virus (CHIKV) is a member of the genus Alpha virus, in the family Togaviridae. Symptoms of Chikungunya includes debilitating arthralgia (joint pain), swelling of joints, stiffness of joints, myalgia (muscular pain), headache, fatigue (weakness), nausea, vomiting and rash and fever. Treatment includes use of NSAIDs.

    Report Highlights

    Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Chikungunya Fever - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Chikungunya Fever (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Chikungunya Fever (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Chikungunya Fever and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 2, 6, 16 and 8 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 7 and 3 molecules, respectively.

    Chikungunya Fever (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Chikungunya Fever (Infectious Disease).
    - The pipeline guide reviews pipeline therapeutics for Chikungunya Fever (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Chikungunya Fever (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Chikungunya Fever (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Chikungunya Fever (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Chikungunya Fever (Infectious Disease).
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Chikungunya Fever (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

    Detailed TOC of Chikungunya Fever - Pipeline Review, H1 2018

    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Global Markets Direct Report Coverage
    Chikungunya Fever - Overview
    Chikungunya Fever - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Pipeline by Universities/Institutes
    Products under Development by Companies
    Products under Development by Universities/Institutes
    Chikungunya Fever - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Route of Administration
    Assessment by Molecule Type
    Chikungunya Fever - Companies Involved in Therapeutics Development
    Bharat Biotech International Ltd
    Ennaid Therapeutics LLC
    Etubics Corp
    Globavir Biosciences Inc
    Hawaii Biotech Inc
    Indian Immunologicals Ltd
    Inovio Pharmaceuticals Inc
    Integral Molecular Inc
    Integrated BioTherapeutics Inc
    Moderna Therapeutics Inc
    Mymetics Corp
    Paradigm Biopharmaceuticals Ltd
    PaxVax Inc
    Profectus BioSciences Inc
    Shionogi & Co Ltd
    Takeda Pharmaceutical Co Ltd
    Themis Bioscience GmbH
    Valneva SE
    Vaxart Inc
    Chikungunya Fever - Drug Profiles
    (chikungunya + Zika) (bivalent) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    BBV-87 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya (viral like particles) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya (virus like particle) vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    chikungunya vaccine - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    CIL-15001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    GBV-006 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Gene Therapy for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    HSRx-431 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IMCKV-063 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies for Equine Encephalitis and Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibodies to Inhibit CHIKV E2 for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mRNA-1388 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    mRNA-1944 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    MV-CHIK - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    pentosan polysulfate sodium - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Peptides for Infectious Diseases - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCV-1002 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SCV-305 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecule to Inhibit NS4 for Chikungunya Fever - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Chikungunya Fever - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Chikungunya Fever - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules for Infectious Disease - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    SVIR-001 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Synthetic Peptides for Chikungunya - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    TAK-507 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Tatbeclin-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    VLA-1553 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Chikungunya Fever - Dormant Projects
    Chikungunya Fever - Product Development Milestones
    Featured News & Press Releases
    Mar 27, 2018: World-first technology developed by Australian biotech company set to revolutionize global vaccine industry
    Mar 13, 2018: VALNEVA Initiates Phase I Clinical Study to Evaluate Its Single-Shot Vaccine Candidate against Chikungunya
    Nov 06, 2017: Themis to Present Phase 2 Interim Results for Chikungunya Vaccine Candidate at ASTMH 2017 Annual Meeting
    Sep 05, 2017: Chikungunya Vaccine Development Towards Phase III Trials Boosted by Innovate UK
    Jul 27, 2017: Themis Bioscience Starts Phase II Clinical Study in Endemic Area
    Jun 05, 2017: Bharat Biotech Begins Phase I Trial of Chikungunya Vaccine
    Jun 05, 2017: NIAID-Sponsored Trial of Experimental Chikungunya Vaccine Begins
    Mar 07, 2017: The Australian Company Testing a Breakthrough Treatment for Ross River
    Jan 09, 2017: Profectus BioSciences Bivalent Vaccine Protects Animals from Infection and Death After Exposure to Chikungunya or Zika Virus
    Dec 19, 2016: UTMB researchers develop first chikungunya vaccine from virus that does not affect people
    Aug 30, 2016: Hawaii Biotech Awarded Grant To Develop Chikungunya Virus Vaccine
    Aug 25, 2016: Leading Chikungunya Vaccine in Clinical Trial Phase 2
    Mar 22, 2016: Inovio’s DNA-based Monoclonal Antibody and DNA Vaccine Provide 100% Protection Against Lethal Chikungunya Virus Challenge in Preclinical Study
    Mar 02, 2015: Themis Bioscience’s Chikungunya Vaccine Study Results Published in The Lancet Infectious Diseases
    Dec 10, 2014: Integral Molecular identifies potent inhibitory antibodies against Chikungunya virus
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Figures, Tables and Charts Available in Chikungunya Fever - Pipeline Review, H1 2018

    List of Tables
    Number of Products under Development for Chikungunya Fever, H1 2018
    Number of Products under Development by Companies, H1 2018
    Number of Products under Development by Companies, H1 2018 (Contd..1), H1 2018
    Number of Products under Development by Universities/Institutes, H1 2018
    Products under Development by Companies, H1 2018
    Products under Development by Companies, H1 2018 (Contd..1), H1 2018
    Products under Development by Universities/Institutes, H1 2018
    Number of Products by Stage and Target, H1 2018
    Number of Products by Stage and Mechanism of Action, H1 2018
    Number of Products by Stage and Route of Administration, H1 2018
    Number of Products by Stage and Molecule Type, H1 2018
    Chikungunya Fever - Pipeline by Bharat Biotech International Ltd, H1 2018
    Chikungunya Fever - Pipeline by Ennaid Therapeutics LLC, H1 2018
    Chikungunya Fever - Pipeline by Etubics Corp, H1 2018
    Chikungunya Fever - Pipeline by Globavir Biosciences Inc, H1 2018
    Chikungunya Fever - Pipeline by Hawaii Biotech Inc, H1 2018
    Chikungunya Fever - Pipeline by Indian Immunologicals Ltd, H1 2018
    Chikungunya Fever - Pipeline by Inovio Pharmaceuticals Inc, H1 2018
    Chikungunya Fever - Pipeline by Integral Molecular Inc, H1 2018
    Chikungunya Fever - Pipeline by Integrated BioTherapeutics Inc, H1 2018
    Chikungunya Fever - Pipeline by Moderna Therapeutics Inc, H1 2018
    Chikungunya Fever - Pipeline by Mymetics Corp, H1 2018
    Chikungunya Fever - Pipeline by Paradigm Biopharmaceuticals Ltd, H1 2018
    Chikungunya Fever - Pipeline by PaxVax Inc, H1 2018
    Chikungunya Fever - Pipeline by Profectus BioSciences Inc, H1 2018
    Chikungunya Fever - Pipeline by Shionogi & Co Ltd, H1 2018
    Chikungunya Fever - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018
    Chikungunya Fever - Pipeline by Themis Bioscience GmbH, H1 2018
    Chikungunya Fever - Pipeline by Valneva SE, H1 2018
    Chikungunya Fever - Pipeline by Vaxart Inc, H1 2018
    Chikungunya Fever - Dormant Projects, H1 2018

    List of Figures
    Number of Products under Development for Chikungunya Fever, H1 2018
    Number of Products under Development by Companies, H1 2018
    Number of Products under Development by Universities/Institutes, H1 2018
    Number of Products by Top 10 Targets, H1 2018
    Number of Products by Stage and Top 10 Targets, H1 2018
    Number of Products by Mechanism of Actions, H1 2018
    Number of Products by Stage and Mechanism of Actions, H1 2018
    Number of Products by Routes of Administration, H1 2018
    Number of Products by Stage and Routes of Administration, H1 2018
    Number of Products by Top 10 Molecule Types, H1 2018
    Number of Products by Stage and Molecule Types, H1 2018

    Keyplayers in Chikungunya Fever - Pipeline Review, H1 2018

    Bharat Biotech International Ltd
    Ennaid Therapeutics LLC
    Etubics Corp
    Globavir Biosciences Inc
    Hawaii Biotech Inc
    Indian Immunologicals Ltd
    Inovio Pharmaceuticals Inc
    Integral Molecular Inc
    Integrated BioTherapeutics Inc
    Moderna Therapeutics Inc
    Mymetics Corp
    Paradigm Biopharmaceuticals Ltd
    PaxVax Inc
    Profectus BioSciences Inc
    Shionogi & Co Ltd
    Takeda Pharmaceutical Co Ltd
    Themis Bioscience GmbH
    Valneva SE
    Vaxart Inc